HCW Biologics Inc.

HCWB Nasdaq SEC CIK 1828673
Follow HCW Biologics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $51.2K +227.9% vs same quarter last year
Net income −$3.2M +29.2% vs same quarter last year
EPS, diluted −$2.83
Operating cash flow −$2.6M +19.1% vs same quarter last year
Revenue by quarter
$394.8K
$5.1K
$6.6K
$15.6K
$27K
$6.5M
$121.7K
$51.2K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$40M−$30M−$20M−$10M$0$10MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$54.2K−$8M
FY24$2.6M−$30M
FY23$2.8M−$25M
FY22$6.7M−$14.9M
FY21$0−$12.9M
FY20$4.1M−$5.8M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%10000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2520%−24270.7%−14677.1%
FY2437.4%−1147.6%−1169.7%
FY2319.7%−905%−879.5%
FY2238.5%−224.3%−221.7%
FY21---
FY20-−142.1%−141.5%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$13.4M
FY24−$14.5M
FY23−$28.7M
FY22−$20.7M
FY21−$11M
FY20−$10.6M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • HCW Biologics
  • Healthcare median
−15000%−10000%−5000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearHCW BiologicsHealthcare median
FY25−14677.1%−30.6%
FY24−1169.7%−47%
FY23−879.5%−58%
FY22−221.7%−80.4%
FY21-−71.9%
FY20−141.5%−62.2%
FY19-−46.3%